-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed's neflamapimod lowers neuronal damage biomarker at higher exposure in Phase 2a aphasia trial

PUBT·11/16/2026 21:02:31
Listen to the news
CervoMed's neflamapimod lowers neuronal damage biomarker at higher exposure in Phase 2a aphasia trial
  • CervoMed presented interim Phase 2a neflamapimod results at CTAD on Nov. 16, 2026, in nonfluent variant primary progressive aphasia.
  • The neuronal damage biomarker remained stable overall among 19 U.S. participants; higher drug exposure was associated with reductions.
  • Participants with lower drug exposure showed increases consistent with untreated disease progression.
  • Neflamapimod was generally well tolerated, with no new safety signals identified.
  • Higher-dose U.K. cohort biomarker data and clinical results are expected at the AD/PD conference in March 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161602PRIMZONEFULLFEED9878688) on November 16, 2026, and is solely responsible for the information contained therein.